Stock Analysis·← Pickers

APLM

Apollomics, Inc.

Apollomics, Inc. (APLM) is currently in a range/mixed trend, trading above both the 50-day and 200-day moving averages. RSI is at 54.7, with 2/3 trend checks passing.

Price
$19.19
2026-07-16
Trend score
2/3
Range / Mixed
RSI (14)
54.7
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

APLM with MA50 and MA200

36.6528.4720.2912.113.9307/3110/2401/2204/1707/15
APLM2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$16.21+18.37% vs price
MA200
$17.71+8.33% vs price
RSI (14)
54.7Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
$12.58–$13.0032.3% below price · 3 touches
Support Quality
3 touches1.8× zone volume
Chart Summary
Trend summary for APLM

Apollomics, Inc. (APLM) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $19.19, and 2 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 18.4% and above the 200-day moving average by 8.3%.

Momentum and stretch context

APLM currently has an RSI reading of 54.7, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the APLM chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Apollomics, Inc.

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

Sector
Healthcare
Industry
Biotechnology
CEO
Hung-Wen Chen
Employees
14
Market cap
$21.2M
Beta
1.44
52-week range
$3.66 – $42.12
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
26 Nov 2021
ISIN
KYG0411D1236
CUSIP
G0411D123
Company profile data from Financial Modeling Prep. APLM listed on NASDAQ.
Share dilution

APLM shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Dec 2025
Shares outstanding (latest)
421.0K
Since Jun 2019
-51.5%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. APLM14 data points from Jun 2019 to Dec 2025.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about APLM

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.